Χώρα: Ισραήλ
Γλώσσα: Αγγλικά
Πηγή: Ministry of Health
BELIMUMAB
GLAXO SMITH KLINE (ISRAEL) LTD
L04AA26
SOLUTION FOR INJECTION
BELIMUMAB 200 MG / 1 ML
S.C
Required
GLAXO OPERATIONS UK LIMITED
BELIMUMAB
Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.
2023-11-30
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) - 1986 The medicine is dispensed according to a physician’s prescription only Benlysta S.C. 200 mg Solution for injection in pre-filled pen Each 1 ml pre-filled pen contains 200 mg belimumab. For the list of the inactive and allergenic ingredients in the medicine, see section 2 - “Important information about some of the ingredients in the medicine” and section 6 - “Additional information”. Read the leaflet carefully in its entirety before using the medicine. This leaflet contains concise information about the medicine. If you have further questions, refer to the physician or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them even if it seems to you that their medical condition is similar. 1. WHAT IS THE MEDICINE INTENDED FOR? Benlysta Subcutaneous 200 mg is indicated as an add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy. Benlysta, in combination with immunosuppressive therapies, is intended for the treatment of adult patients with active lupus nephritis. Therapeutic group: selective immunosuppressant. Lupus is a disease in which the immune system (the system that fights infection) attacks your own cells and tissues, causing inflammation and organ damage. The disease can affect almost any organ in the body, and is thought to involve a type of white blood cells called B cells. Benlysta S.C. 200 mg contains belimumab (a human monoclonal antibody). It reduces the number of B cells in your blood by blocking the action of BLyS, a protein that helps B cells live longer and is found in high levels in people with lupus. You will be given Benlysta S.C. 200 mg in addition to your usual treatment for lupus. 2. BEFORE USING THE MEDICINE Do not use the medicine if: • you are sensitive (allergic) to belimumab or to an Διαβάστε το πλήρες έγγραφο
Page 1 of 21 Benlysta S.C. 200 mg 1. NAME OF THE MEDICINAL PRODUCT Benlysta S.C. 200 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Pre-filled pen Each 1-mL pre-filled pen contains 200 mg of belimumab. Pre-filled syringe Each 1-mL pre-filled syringe contains 200 mg of belimumab. Belimumab is a human, IgG1λ monoclonal antibody, produced in a mammalian cell line (NS0) by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection in pre-filled pen (injection) Solution for injection in pre-filled syringe (injection) A clear to opalescent, colourless to pale yellow solution, with a pH of 6. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy (see section 5.1). Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (see sections 4.2 and 5.1). Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system lupus. Benlysta has not been studied in combination with other biologics. Use of Benlysta is not recommended in these situations. 4.2 Posology and method of administration Benlysta treatment should be initiated and supervised by a qualified physician experienced in the diagnosis and treatment of SLE. It is recommended that the first subcutaneous injection of Benlysta should be under the supervision of a healthcare professional in a setting that is sufficiently qualified to manage hypersensitivity reactions, if necessary. The healthcare professional must provide proper training in subcutaneous technique and education about signs and symptoms of hypersensitivity reactions (see section 4.4). A patient may self-inject or the patient caregiver may administer Benlysta after the h Διαβάστε το πλήρες έγγραφο